A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

摘要: Background & Aims Protease inhibitor triple therapy for hepatitis C virus (HCV) infection (boceprevir or telaprevir with pegylated interferon and ribavirin) has been shown to increase rates of sustained virologic response in phase 3 trials. We investigated the proportion patients who began this regimen 12 months after Food Drug Administration approval boceprevir United States. Methods performed a retrospective cross-sectional study 487 HCV genotype 1 (396 did not receive therapy, 91 had begun telaprevir), were seen at hepatology practices Dallas Miami from June 2011 through February 2012. The subjects predominantly middle-aged, non-Hispanic white, privately insured; 50% treatment-naive, most advanced fibrosis. compared features initiated those deferred it. Treated followed determine discontinuation rate first weeks treatment. Results Of assessed, only 18.7% same percentage as receiving dual (pegylated before was approved treatment Reasons deferring included relative contraindications (50.5%), patient choice (22.5%), less liver disease (17.4%). Among treated patients, 15% discontinued prematurely because serious adverse events. On basis multivariate analysis, factors associated initiation prior relapse (odds ratio [OR], 4.6; 95% confidence interval [CI], 2.1–9.9) fibrosis stage (OR, 9.1; CI, 3.1–27) 4 9.0; 3.3–25) but hepatic decompensation. Conclusions Only received telaprevir. This low might result concerns side effects recognition that more effective medications could be available future.